Risk factors of gene-resistant mutations in different nucleosides.
An P, Bian L, Yin B, Lv D, Cao YX, Wu X.
An P, et al.
Hepatogastroenterology. 2012 Jan-Feb;59(113):228-30. doi: 10.5754/hge11247.
Hepatogastroenterology. 2012.
PMID: 22260834
Clinical Trial.
METHODOLOGY: A total of 320 patients with CHB were randomly divided into lamivudine (LAM, 107 cases), adefovir (ADV, 106 cases) and entecavir (ETV, 107 cases) groups, and P gene mutations of HBV were regularly detected. Kaplan-Meier and Cox regression analysis were perform …
METHODOLOGY: A total of 320 patients with CHB were randomly divided into lamivudine (LAM, 107 cases), adefovir (ADV, 106 cases) and entecavi …